Vaccinia as a vector for gene delivery

Bibliography

• ••
   Google Scholar
• FENNER F, WITTEK R, DUMBELL KR: Vaccinia virus: the tool for smallpox eradication. In: The Orthopoxviruses. Fenner F, Wittek R, Dumbell KR (Eds), Adademic Press, Inc., New York, USA (1989):143–170.
   Google Scholar
• FULGINITI VA, PAPIER A, LANE JM, NEFF JM, HENDERSON DA: Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin. Infect. Dis. (2003) 37:241–250.
   Google Scholar
• A thorough review of smallpox vaccine and expected normal outcomes.
   Google Scholar
• MOSS B: Vaccinia virus: a tool for researchand vaccine development. Science (1991) 252:1662–1667.
   PubMed Web of Science ®Google Scholar
• SMITH GL, MOSS B: Infectious poxvirusvectors have capacity for at least 25,000 base pairs of foreign DNA. Gene (1983) 25:21–28.
   PubMed Web of Science ®Google Scholar
• MOSS B: Poxvirus vectors: cytoplasmic expression of transferred genes. Carr. Opin. Genet. Dev. (1992) 3:86–90.
   Google Scholar
• MOSS B: Poxviridae: the viruses and their replication. In: Fields Virology Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia, USA (1996):2637–2671.
   Google Scholar
• SUTTER G, MOSS B: Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev. Biol. Stand. (1995) 84:195–200.
   PubMedGoogle Scholar
• GOEBEL SJ, JOHNSON GP, PERKUS ME, DAVIS SW, WINSLOW JP, PAOLETTI E: The complete DNA sequence of vaccinia virus. Virology (1990) 179:247–266.
   PubMed Web of Science ®Google Scholar
• ANTOINE G, SCHEIFLINGER F, DORNER F, FALKNER FG: The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 242:365–396.
   Google Scholar
• DUBOCHET J, ADRIAN M, RICHTER K, GARCES J, WITTEK R: Structure of intracellular mature vaccinia virus observed by cryoelectron microscopy. Virol (1994) 68:1935–1941.
   Web of Science ®Google Scholar
• SMITH GL, VANDERPLASSCHEN A: Extracellular enveloped vaccinia virus: entry, egress, and evasion. In: Corona viruses and Arteri viruses. Enjuanes A (Ed.), Plenum Press, New York, USA (1998):395–414.
   Google Scholar
• LALANI AS, MASTERS J, ZENG W et aL:Use of chemokine receptors by poxviruses. Science (1999) 286:1968–1971.
   PubMed Web of Science ®Google Scholar
• VANDERPLASSCHEN A, HOLLINSHEAD M, SMITH GL: Intracellular and extracellular vaccinia virions enter cells by different mechanisms.' Gen. Viral. (1998) 79:877–887.
   PubMed Web of Science ®Google Scholar
• VANDERPLASSCHEN A, SMITH GL: A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors.' Vim/. (1997) 71:4032–4041.
   Web of Science ®Google Scholar
• BETAKOVA T, WOLFFE EJ, MOSS B: Membrane topology of the vaccinia virus A17L envelope protein. Virology (1999) 261(2):347–356.
   PubMed Web of Science ®Google Scholar
• WOLFFE EJ, MOORE DM, PETERS PJ, MOSS B: Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. Vim/. (1996) 70(5):2797–2808.
   Web of Science ®Google Scholar
• SANDERSON CM, HOLLINSHEAD M, SMITH GL: The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles.' Gen. Viral. (2000) 81:47–58.
   PubMed Web of Science ®Google Scholar
• CHUNG CS, HSIAO JC, CHANG YS, CHANG W: A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate.' Virol (1998) 72:1577–1585.
   PubMed Web of Science ®Google Scholar
• SODEIK B, CUDMORE S, ERICSSON M, ESTEBAN M, NILES EG, GRIFFITHS G: Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. Viral. (1995) 69:3560–3574.
   PubMed Web of Science ®Google Scholar
• HSIAO JC, CHUNG CS, CHANG W: Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells." Viral. (1999) 73:8750–8761.
   PubMed Web of Science ®Google Scholar
• WALLENGREN K, RISCO C, KRIJNSE-LOCKERJ, ESTEBAN M, RODRIGUEZ D: The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology (2001) 290:143–152.
   PubMedGoogle Scholar
• LAW M, SMITH GL: Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology (2001) 280:132–142.
   PubMed Web of Science ®Google Scholar
• GALMICHE MC, RINDISBACHER L, WELS W, WITTEK R, BUCHEGGER F: Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting.' Gen. Virol. (1997) 78:3019–3027.
   PubMed Web of Science ®Google Scholar
• KATZ E, WOLFFE EJ, MOSS B: The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. Vim/. (1997) 71:3178–3187.
   Web of Science ®Google Scholar
• BROYLES SS, LIU X, ZHU M, KREMER M: Transcription factor YY1 is a vaccinia virus late promoter activator. Biol. Chem. (1999) 274:35662–35667.
   Web of Science ®Google Scholar
• ZHU M, MOORE T, BROYLES SS: A cellular protein binds vaccinia virus late promoters and activates transcription M vitro.' Virol (1998) 72:3893–3899.
   PubMed Web of Science ®Google Scholar
• BROYLES SS:Vaccinia virus transcription. Gen. Viral. (2003) 84:2293–2303.
   PubMed Web of Science ®Google Scholar
• TOLONEN N, DOGLIO L, SCHEICH S, LOCKER JK: Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. MM. Biol. Cell (2001) 12:2031–2046.
   PubMed Web of Science ®Google Scholar
• SODEIK B, KRIJNSE-LOCKER J: Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host? Trends Microbial. (2002) 10:15–24.
   Google Scholar
• CARROLL MW, MOSS B: Poxviruses as expression vectors. Curt: Opin. Biotech. (1997) 8:573–577.
   PubMed Web of Science ®Google Scholar
• DOMI A, MOSS B: Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99:12415–12420.
   PubMed Web of Science ®Google Scholar
• YAO, XD, EVANS DH: High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. " Viral. (2003) 77:7281–7290.
   PubMed Web of Science ®Google Scholar
• YUEN L, MOSS B: Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA (1987) 84:6417–6421.
   PubMed Web of Science ®Google Scholar
• BULLER RIVI, CHAKRABARTI S, COOPER JA, TWARDZIK DR, MOSS B: Deletion of the vaccinia virus growth factor gene reduces virus virulence.' Viral. (1988) 62:866–874.
   PubMed Web of Science ®Google Scholar
• FATHI Z, DYSTER LM, SETO J, CONDIT RC, NILES EG: Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus. " Gen. Virol (1991) 72:2733–2737.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI S, SISLER JR, MOSS B: Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques (1997) 23:1094–1097.
   PubMed Web of Science ®Google Scholar
• EARL PL, MOSS B: Expression of proteins in mammalian cells using vaccinia viral vectors. In: Current Protocols M Molecular Biology Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (Eds), Greene/Wiley Interscience, New York, USA (1998):16.
   Google Scholar
• BOYLE DB, COUPAR BE: A dominant selectable marker for the construction of recombinant poxviruses. Gene (1988) 65(1):123–128.
   PubMed Web of Science ®Google Scholar
• PERKUS ME, LIMBACH K, PAOLETTI E: Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.Virol (1989)63(9):3829–3836.
   Google Scholar
• PANICALI D, PAOLETTI E: Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Nati Acad. Sci. USA (1982) 79:4927–4931.
   PubMed Web of Science ®Google Scholar
• MACKETT M, SMITH GL, MOSS B: Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Nati Acad. Sci. USA (1982) 79:7415–7419.
   PubMed Web of Science ®Google Scholar
• MOSS B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Nati Acad. Sci. USA (1996) 93:11341–11348.
   PubMed Web of Science ®Google Scholar
• COCHRAN MA, MACKETT M, MOSS B: Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc. Natl. Acad. Sci. USA (1985) 82(1):19–23.
   PubMed Web of Science ®Google Scholar
• TSUNG K, YIM JH, MARTI W, BULLER RM, NORTON JA: Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol (1996) 70(1):165–171.
   PubMed Web of Science ®Google Scholar
• FULGINITI VA, PAPIER A, LANE JM, NEFF JM, HENDERSON DA: Smallpox vaccination: a review, part II. Adverse events. Gin. Infect. D (2003) 37:251–271.
   PubMed Web of Science ®Google Scholar
• •A very detailed review on possible adverse events after smallpox vaccination.
   Google Scholar
• ••
   Google Scholar
• GURVICH EB, VILESOVA IS: Vaccinia virus in postvaccinal encephalitis. Acta Virol (1983) 27(2):154–159.
   PubMed Web of Science ®Google Scholar
• ENSERINK M: Public health. Treating vaccine reactions: two lifelines, but no guarantees. Science (2002) 298:2313.
   Google Scholar
• ENSERINK M: Bioterrorism. In search of akinder, gentler vaccine. Science (2002) 296:1594.
   PubMedGoogle Scholar
• DEMKOWICZ WE JR, LITTAUA RA, WANG J, ENNIS FA: Human cytotoxic T-cell memory: long-lived responses to vaccinia virus.Virol. (1996) 70:2627–2631.
   Web of Science ®Google Scholar
• HAMMARLUND E, LEWIS MW, HANSEN SG et al.: Duration of antiviral immunity after smallpox vaccination. Nat. Med. (2003). 9:1131–1137.
   PubMed Web of Science ®Google Scholar
• ••A detailed analysis of the duration of both cellular and hurnoral immunity after smallpox vaccination, which may be important for future vaccination procedures.
   Google Scholar
• AMARA RR, NIGAM P, HARMA S, LIU J, BOSTIK V: Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. Virol. (2004). 78:3811–3816.
   Web of Science ®Google Scholar
• SMITH GL, SYMONS JA, KHANNA A, VANDERPLASSCHEN A, ALCAMI A: Vaccinia virus immune evasion. Immunol. Rev (1997) 159:137–154.
   PubMed Web of Science ®Google Scholar
• SMITH GL, VANDERPLASSCHEN A, LAW M: The formation and function of extracellular enveloped vaccinia virus. Gen. Virol. (2002) 83:2915–2931.
   PubMed Web of Science ®Google Scholar
• MCCART JA, PUHLMANN M, LEE J et al.: Complex interactions between the replicating oncolytic effect and the enzyme/ prodrug effect of vaccinia-mediated tumor regression. Gene Ther. (2000) 7:1217–1223.
   PubMed Web of Science ®Google Scholar
• PUHLMANN M, BROWN CK, GNANT M et al.: Vaccinia as a vector for tumor directed gene therapy: biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther. (2000) 7:66–73.
   PubMed Web of Science ®Google Scholar
• ALCAMI A, KOSZINOWSKI UH: Viral mechanisms of immune evasion. Trends Microbial. (2000). 8:410–418.
   PubMed Web of Science ®Google Scholar
• SYMONS JA, ALCAMI A, SMITH GL:Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 81:551–560.
   PubMed Web of Science ®Google Scholar
• NAJARRO P, TRAKTMAN P, LEWIS JA:Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Statl activation.' Virol. (2001) 75:3185–3196.
   PubMed Web of Science ®Google Scholar
• ADAM BL, VLAHOU A, SEMMES 0J, WRIGHT GL JR: Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics (2001) 1:1264-1270. so. SEET BT, MCFADDEN G: Viral chemokine-binding proteins. Leukoc. Biol. (2002) 72:24–34.
   Google Scholar
• ALCAMI A, SYMONS JA, COLLINS PD,WILLIAMS TJ, SMITH GL: Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. Immunol. (1998) 160:624–633.
   Web of Science ®Google Scholar
• MAHALINGAM S, KARUPIAH G: Modulation of chemokines by poxvirus infections. Cirri: Opin. Immunol (2000) 12:409–412.
   PubMed Web of Science ®Google Scholar
• SMITH VP, BRYANT NA, ALCAMI A: Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. Gen. Virol. (2000) 81:1223–1230.
   PubMed Web of Science ®Google Scholar
• CALDERARA S, XIANG Y, MOSS B: Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology (2001) 279:22–26.
   PubMed Web of Science ®Google Scholar
• ANGELINI G, GARDELLA S, ARDY M et al.: Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Nati Acad. Sci. USA (2002) 99:1491–1496.
   PubMed Web of Science ®Google Scholar
• NOVICK D, KIM SH, FANTUZZI G, REZNIKOV LL, DINARELLO CA, RUBINSTEIN M: Interleukin-18 binding protein: a novel modulator of the Thl cytokine response. Immunity (1999) 10:127–136.
   PubMed Web of Science ®Google Scholar
• ENGELSTAD M, HOWARD ST, SMITH GL: A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 188:801–810.
   PubMed Web of Science ®Google Scholar
• BOWIE A, KISS-TOTH E, SYMONS JA,SMITH GL, DOWER SK, O'NEILL LA: A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. USA (2000) 97:10162–10167.
   PubMed Web of Science ®Google Scholar
• HOWARD ST, CHAN YS, SMITH GL: Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology (1991) 180:633–647.
   PubMed Web of Science ®Google Scholar
• ALBORES-SAAVEDRA J, HEFFESS C, HRUBAN RH, KLIMSTRA D, LONGNECKER D: Recommendations for the reporting of pancreatic specimens containing malignant tumors. The Association of Directors of Anatomic and Surgical Pathology. Am. I Clin. Pathol. (1999) 111:304–307.
   Web of Science ®Google Scholar
• VAN DEN BROEK M, BACHMANN ME KOHLER G et al.: IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. Immunoi (2000) 164:371–378.
   Google Scholar
• DEONARAIN R, ALCAMI A, ALEXIOU M, DALLMAN MJ, GEWERT DR, PORTER AC: Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. Viral. (2000) 74:3404–3409.
   PubMed Web of Science ®Google Scholar
• GHERARDI MM, RAMIREZ JC, ESTEBAN M: IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. Gen. Virol. (2003). 84:1961–1972.
   PubMed Web of Science ®Google Scholar
• GRACE JT JR, MIRAND EA: Yaba virus infection in humans. Exp. M....Po' Surg. (1965) 23:213–216.
   PubMedGoogle Scholar
• HU Y, LEE J, MCCART A et al.: Yaba like disease virus: an alternating replicating pox vector for cancer gene therapy. Vim/. (2001) 75:10300–10308.
   Web of Science ®Google Scholar
• PAOLETTI E: Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA (1996) 93:11349–11353.
   PubMed Web of Science ®Google Scholar
• BARTLETT DL: Vaccinia virus. Monogr. Virol. (2001) 22:129–158.
   Google Scholar
• ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9:1001–1012.
   PubMed Web of Science ®Google Scholar
• SHARMA DP, RAMSAY AJ, MAGUIRE DJ, ROLPH MS, RAMSHAW IA: Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Vim/. (1996) 70:7103-7107. ao. ALVAREZ-VALLINA L, AGHA-MOHAMMADI S, HAWKINS RE, RUSSELL SJ:
   Google Scholar
• ••
   Google Scholar
• •• Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J. Immunol. (1997) 159:5889–5895.
   Google Scholar
• BAXBY D: Smallpox vaccination techniques: from knives and forks to needles and pins. Vaccine (2002) 20(16):2140–2149.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO MJ, MAGUIRE HC JR, EISENLOHR LC et al.: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene The]: (1998) 6:409–422.
   Web of Science ®Google Scholar
• LATTIME EC, LEE SS, EISENLOHR LC, MASTRANGELO MJ: In situ cytokine gene transfection using vaccinia virus vectors. Semin. Oncol. (1996) 23:88–100.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, BLAESE RM, BRENNER MK et al: Human gene marker/therapy clinical protocols. Hum. Gene The]: (1999) 10:3067–3123.
   PubMedGoogle Scholar
• EDERJP, KANTOFF PW, ROPER K et al: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6:1632–1638.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18:3964–3973.
   PubMed Web of Science ®Google Scholar
• GREINER JW, ZEYTIN H, ANVER MR,SCHLOM J: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. (2002) 62:6944–6951.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO MJ, MAGUIRE HC JR, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. (2000) 465:391–400.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, BALCH CM et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial../. Am. Coll. &rig. (1998) 187:69–77.
   Web of Science ®Google Scholar
• HERSEY P, EDWARDS A, COATES A, SHAW H, MCCARTHY W, MILTON G: Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol. Immunother (1987) 25:257–265.
   PubMed Web of Science ®Google Scholar
• HERSEY P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann. NY Acad. Sci. (1993) 690:167–177.
   PubMed Web of Science ®Google Scholar
• WYATT LS, EARL PL, ELLER LA, MOSS B: Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. (2004). Proc. Nati Acad. Sci. USA (2004) 101:4590–4595.
   PubMed Web of Science ®Google Scholar
• EARL PL, AMERICO JA, WYATT LS et al.: Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 428:182–185.
   PubMed Web of Science ®Google Scholar
• ••A highly attenuated MVA strain as avaccine showed better safety and high efficacy in generating immunity and protection from monkeypox.
   Google Scholar
• HERNAIZ-DRIEVER P, RABKIN SD: Replication-competent viruses for cancer therapy. Monogr: Virol. (2001) 22:1–187.
   Google Scholar
• KIRN D: Virotherapy for cancer: currentstatus, hurdles and future directions. Cancer Gene Ther. (2002) 9:959–960.
   PubMed Web of Science ®Google Scholar
• KIRN D, NICULESCU-DUVAZ I, HALLDEN G, SPRINGEER CJ: The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. (2002) 8:S68–S73.
   Google Scholar
• KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. (2001) 7:781–787.
   PubMed Web of Science ®Google Scholar
• CHIOCCA EA: Oncolytic viruses. Nat. Rev Cancer (2002) 2:938–950.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, EDELMAN J: Selectively replicating viral vectors. Cancer Gene The]: (2002) 9:987–1000.
   PubMed Web of Science ®Google Scholar
• MCCART JA, WARD JM, LEE J et al.: Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. (2001) 61:8751–8757.
   PubMed Web of Science ®Google Scholar
• ••The double deletion of tk and vgfimproved the safety without compromising the efficacy for oncolytic virotherapy.
   Google Scholar
• GNANT ME PUHLMANN M, ALEXANDER HR JR, BARTLETT DL: Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice. Cancer Res. (1999) 59:3396–3404.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, HAENEL T, HIMBECK R et al.: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther. (2000) 7:663–670.
   PubMed Web of Science ®Google Scholar
• NAIK A, MCCART JA, XU H et al.: Intravenous and isolated limb perfusion delivery of a tumor selective vaccinia virus mutant in non-human primates. Mol. The]: (2001) 3:s303–s304.
   Google Scholar
• GNANT M, NOLL L, IRVINE KR et al: Tumor specific gene delivery using recombinant vaccinia virus in a rabbit model of unresectable liver metastases - pattern of gene expression, vector elimination and immune response. Natl. Cancer Inst. (1999) 91:1744–1750.
   Google Scholar
• PEPLINSKI GR, TSUNG K, CASEY MJ et al.: In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-lbeta. Cancerj Sci. Am. (1996) 2:21–27.
   PubMedGoogle Scholar
• ROENIGK HH JR, DEODHAR S, ST JACQUES R, BURDICK K: Immunotherapy of malignant melanoma with vaccinia virus. Arch. Dermatol (1974) 109:668–673.
   PubMed Web of Science ®Google Scholar
• ISRAEL RM: Treatment of warts by vaccination. Arch. Dermatol. (1969) 100:222–223.
   PubMed Web of Science ®Google Scholar
• HANSEN RM, LIBNOCH JA: Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch. Intern. Med. (1978) 138:1137–1138.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev (2001) 14:382–397.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Cidofovir in the treatment of poxvirus infections. Antiviral Res. (2002) 55:1–13.
   PubMed Web of Science ®Google Scholar
• SMEE DF, BAILEY KW, WONG MH, SIDWELL RW: Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. (2001) 52:55–62.
   PubMed Web of Science ®Google Scholar
• DOROZYNSKI A, ANDERSON A: Deaths in vaccine trials trigger French inquiry. Science (1991) 252:501–502.
   PubMed Web of Science ®Google Scholar
• TRAKTMAN P, LIU K, DEMASI J, ROLLINS R, JESTY S, UNGER B: Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: construction and characterization of a tetracycline-inducible recombinant. Virol (2000) 74(8):3682–3695.
   Web of Science ®Google Scholar
• RAMSHAW IA, ANDREW ME, PHILLIPS SM, BOYLE DB, COUPAR BE: Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature (1987) 329:545–546.
   PubMed Web of Science ®Google Scholar
• KOHONEN-CORISH MR, KING NJ, WOODHAMS CE, RAMSHAW IA: Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. Immunol (1990) 20:157–161.
   PubMed Web of Science ®Google Scholar
• FLEXNER C, MOSS B, LONDON WT, MURPHY BR: Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine (1990) 8:17–22.
   PubMed Web of Science ®Google Scholar
• GROSENBACH DW, HRUBY DE: Biology of vaccinia virus acylproteins. Front. Biosci (1998) 3:d354–d364.
   Google Scholar
• COONEY EL, COLLIER AC, GREENBERG PD et al.: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 337:567–572.
   PubMed Web of Science ®Google Scholar
• PICARD 0, ACHOUR A, BERNARD J et al.: A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. I Acquir. Immune Defic. Synch: (1992) 5:539–546.
   Google Scholar
• GRAHAM BS, GORSE GJ, SCHWARTZ DH et al.: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp16 0-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.' Infect. Dis. (1994) 170:782–786.
   Google Scholar
• TSANG KY, ZAREMBA S, NIERODA CA, ZHU MZ, HAMILTON JM, SCHLOM J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Natl. Cancer Last (1995) 87:982–990.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347:1523–1527.
   PubMed Web of Science ®Google Scholar
• MCANENY D, RYAN CA, BEAZLEY RIVI, KAUFMAN HL: Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol (1996) 3:495–500.
   PubMed Web of Science ®Google Scholar
• SANDA MG, SMITH DC, CHARLES LG et al.: Recombinant vaccinia-PSA (Prostvac) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 53:260–266.
   PubMed Web of Science ®Google Scholar
• CONRY RM, ALLEN KO, LEE S, MOORE SE, SHAW DR, LOBUGLIO AF: Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res (2000) 6:34–41.
   PubMed Web of Science ®Google Scholar
• KANESA-THASAN N, SMUCNY JJ, HOKE CH et al.: Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine (2000) 19:483–491.
   PubMed Web of Science ®Google Scholar
• MCCLAIN DJ, SUMMERS PL, HARRISON SA, SCHMALJOHN AL, SCHMALJOHN CS: Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. Med. Virol (2000) 60:77–85.
   PubMed Web of Science ®Google Scholar
• ADAMS M, BORYSIEWICZ L, FIANDER A et al.: Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 19:2549–2556.
   PubMed Web of Science ®Google Scholar
• HANKE T, MCMICHAEL AJ, MWAU M et al.: Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine (2002) 20:1995–1998.
   PubMed Web of Science ®Google Scholar
• ZAJAC P, OERTLI D, MARTI W et a/.: Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Tiler. (2003) 14:1497–1510.
   Google Scholar
• RAMSHAW IA, RAMSAY AJ: The prime-boost strategy: exciting prospects for improved vaccination. ImmunoL Today (2000) 21:163–165.
   PubMedGoogle Scholar
• KWAK H, MUSTAFA W, SPEIRS K, ABDOOL AJ, PATERSON Y, ISAACS SN: Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion. Virology (2004) 322:337–348.
   PubMed Web of Science ®Google Scholar
• WASILENKO ST, STEWART TL, MEYERS AF, BARRY M: Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc. Natl. Acad. Sci. USA (2003) 100:14345–14350.
   PubMed Web of Science ®Google Scholar